1,238 Spam-Free Article(s) Found
Sort:
Like
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Tuesday’s Close
ONCE Spark Therapeutics, Inc. $57.05 $2.14B N/A
Article Searches
Novartis Q2 Earnings Miss, Sales Top on Cosentyx, Entresto http://www.zacks.com/stock/news/312077/novartis-q2-earnings-miss-sales-top-on-cosentyx-entresto?cid=CS-ZC-FT-312077 Jul 18, 2018 - Novartis (NVS) misses on Q2 earnings but beats sales on the back of continued momentum from Cosentyx and Entresto. Oncology franchise also exhibits strong growth.
$100 Million Was Once Big Money for a Start-Up. Now, It’s Common. https://www.nytimes.com/2018/08/14/technology/venture-capital-mega-round.html?partner=rss&emc=rss Aug 14, 2018 - Known as a mega-round in Silicon Valley, large-scale fund raising is producing a frenzy around tech companies with enough reach and momentum to absorb a large check.
Trade War Once Again Gather Steam http://www.zacks.com/stock/news/323637/trade-war-once-again-gather-steam?cid=CS-ZC--323637 Sep 18, 2018 - Trade War Once Again Gather Steam
Novartis Gets Positive CHMP Opinion for Drugs, Biosimilar http://www.zacks.com/stock/news/324579/novartis-gets-positive-chmp-opinion-for-drugs-biosimilar?cid=CS-ZC-FT-324579 Sep 24, 2018 - Novartis (NVS) gets positive CHMP opinion for a label expansion of Gilenya, gene therapy, and a biosimilar of Neulasta.
Novartis Presents Positive Data on Sickle Cell Disease Drug http://www.zacks.com/stock/news/327300/novartis-presents-positive-data-on-sickle-cell-disease-drug?cid=CS-ZC-FT-327300 Oct 10, 2018 - Novartis (NVS) announces positive results from a post hoc analysis of the phase II study, SUSTAIN, on pipeline candidate, crizanlizumab, being published in the American Journal of Hematology.
uniQure Up on Positive Data From Mid-Stage Hemophilia Study http://www.zacks.com/stock/news/337966/uniqure-up-on-positive-data-from-mid-stage-hemophilia-study?cid=CS-ZC-FT-337966 Nov 16, 2018 - uniQure's (QURE) gene therapy candidate, AMT-061, demonstrates significant improvement in hemophilia B patients in a mid-stage study. Investors' sentiment improves.
Biotech Stock Roundup: Pipeline Updates From CELG & VRTX, ZFGN Plunges on Hold News http://www.zacks.com/stock/news/339665/biotech-stock-roundup-pipeline-updates-from-celg-vrtx-zfgn-plunges-on-hold-news?cid=CS-ZC-FT-339665 Nov 28, 2018 - Pipeline and regulatory updates are the key highlights in the biotech sector this week.
5 Gene Therapy Stocks to Enrich Your Portfolio http://www.zacks.com/stock/news/356924/5-gene-therapy-stocks-to-enrich-your-portfolio?cid=CS-ZC-FT-356924 Feb 26, 2019 - Gene therapy stocks have not only soared on Roche-Spark deal news but are also poised to make the most of the next gene revolution.
Biotech Stock Roundup: ONCE, CMTA Soar on Merger News, Other Pipeline Updates http://www.zacks.com/stock/news/357193/biotech-stock-roundup-once-cmta-soar-on-merger-news-other-pipeline-updates?cid=CS-ZC-FT-357193 Feb 27, 2019 - Key highlights of the past week are merger agreements, and regulatory and pipeline developments.
Biogen to Acquire Gene-Therapy Company Nightstar for $800M http://www.zacks.com/stock/news/357776/biogen-to-acquire-gene-therapy-company-nightstar-for-%24800m?cid=CS-ZC-FT-357776 Mar 05, 2019 - Biogen (BIIB) to acquire gene-therapy company, Nightstar Therapeutics to accelerate entry into ophthalmology space.
<<<Page 120>